Non-coding RNAs as a Critical Player in the Regulation of Inflammasome in Inflammatory Bowel Diseases; Emphasize on lncRNAs

• Published in: Cell biochemistry and biophysics
• Main Authors: Salim Abed, Hussein, Oghenemaro, Enwa Felix, Kubaev, Aziz, Jeddoa, Zuhair Mohammed Ali, S, RenukaJyothi, Sharma, Shilpa, Vashishth, Raghav, Jabir, Majid S, Jawad, Sabrean Farhan, Zwamel, Ahmed Hussein
• Format: Journal Article
• Language: English
• Published: United States 19-10-2024
• Subjects: Non-coding RNAs (ncRNAs); Inflammasome; Inflammation; Inflammatory bowel disease (IBD); Long non-coding RNA (lncRNAs)
• ISSN: 1085-9195; 1559-0283; 1559-0283
• DOI: 10.1007/s12013-024-01585-2

Inflammatory bowel disease (IBD) is an idiopathic disease caused by a dysregulated immune response to host intestinal microflora. A hyperactive inflammatory and immunological response in the gut has been shown to be one of the disease's long-term causes despite the complexity of the clinical pathology of IBD. The innate immune system activator known as human gut inflammasome is thought to be a significant underlying cause of pathology and is closely linked to the development of IBD. It is essential to comprehend the function of inflammasome activation in IBD to treat it effectively. Systemic inflammasome regulation may be a proper therapeutic and clinical strategy to manage IBD symptoms since inflammasomes may have a significant function in IBD. Non-coding RNAs (ncRNAs) are a type of RNA transcript that is incapable of encoding proteins or peptides. In IBD, inflammation develops and worsens as a result of its imbalance. Culminating evidence has been shown that ncRNAs, and particularly long non-coding RNAs (lncRNAs), may play a role in the regulation of NLR family pyrin domain containing 3 (NLRP3) inflammasome activation in IBD. The relationship between IBD and the gut inflammasome, as well as current developments in IBD research and treatment approaches, have been the main topics of this review. We have covered inflammasomes and their constituents, results from in vivo research, inflammasome inhibitors, and advancements in inflammasome-targeted therapeutics for IBD.